<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739269</url>
  </required_header>
  <id_info>
    <org_study_id>UW 12-358</org_study_id>
    <nct_id>NCT02739269</nct_id>
  </id_info>
  <brief_title>Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF</brief_title>
  <official_title>A Randomised Trial to Compare Antral Follicle Count and Serum Anti-Mullerian Hormone Level for Determination of Gonadotrophin Dosing in In-vitro Fertilisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized trial to compare the use of AFC and serum AMH as the basis
      for gonadotrophin dosing in in-vitro fertilization treatment.

      The hypothesis is that the use of serum AMH as the criterion for determination of
      gonadotrophin dosing in IVF treatment results in more optimal ovarian response than AFC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing the first-time IVF treatment cycle using either conventional insemination
      technique or intracytoplasmic sperm injection at Queen Mary Hospital will be invited to
      participate in this study. Participating subjects will be randomized into either (i) AFC or
      (ii) AMH group, where the gonadotrophin dosing will be determined based on the baseline AFC
      and serum AMH respectively as assessed one month before the IVF treatment. Randomisation will
      be performed according to a computer-generated list which will be read by an independent
      research nurse. That research nurse will assign the initial gonadotrophin dose according to
      the study protocol.

      In the AFC group, starting dose of gonadotrophin will be determined based on serum AMH
      concentration as follows:

      AFC &lt;= 5: 300 IU daily AFC &gt;5 and &lt;=15: 225 IU daily AFC &gt;15: 150 IU daily

      In the AMH group, starting dose of gonadotrophin will be determined based on serum AMH
      concentration as follows:

      AMH &lt;= 1.0 ng/ml: 300 IU daily AMH &gt;1.0 and &lt;=3.3 ng/ml: 225 IU daily AMH &gt;3.3 ng/ml: 150 IU
      daily

      The clinician and patient will both be blinded to the randomization throughout the course of
      treatment. The proportion of subjects having appropriate ovarian response, defined as the
      number of oocytes retrieved being 6 to 14 inclusive, will be compared between the two arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2016</start_date>
  <completion_date type="Actual">April 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Having Desired Ovarian Response</measure>
    <time_frame>One single time point, i.e. at the time of oocyte retrieval</time_frame>
    <description>Percentage of subjects with number of oocytes retrieved being between 6 and14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Requiring Step-up or Step-down of Gonadotrophin Dose Upon First Ultrasound Tracking</measure>
    <time_frame>8th day of ovarian stimulation</time_frame>
    <description>The dose of gonadotrophin will be adjusted according to the ovarian response: if 5 or less follicles growing beyond 10 mm --&gt; step up if more than 15 follicles growing beyond 10 mm --&gt; step down</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>AMH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Serum AMH measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AFC group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>AFC measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum AMH measurement</intervention_name>
    <description>Serum AMH is measured one month before the IVF treatment</description>
    <arm_group_label>AMH group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AFC measurement</intervention_name>
    <description>Early follicular phase AFC is measured one month before the IVF treatment</description>
    <arm_group_label>AFC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects undergoing the first IVF cycle during the study period.

        Exclusion Criteria:

          -  Body mass index &gt;=30 kg/m2

          -  Subjects in repeated IVF cycles

          -  Subjects undergoing IVF treatment using donor oocytes

          -  Subjects undergoing pre-implantation genetic diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hang Wun Raymond Li, MBBS, FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <results_first_submitted>May 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Hang Wun Raymond Li</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ovarian response</keyword>
  <keyword>anti-Mullerian hormone</keyword>
  <keyword>antral follicle count</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No such plan at the moment</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02739269/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 200 women who were undergoing in vitro fertilisation treatment in Queen Mary Hospital, Hong Kong, were recruited.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AMH Group</title>
          <description>Serum AMH measurement
Gonadotrophin dosing was based on serum AMH measured one month before the IVF treatment</description>
        </group>
        <group group_id="P2">
          <title>AFC Group</title>
          <description>AFC measurement
Gonadotrophin dosing was based on early follicular phase AFC measured one month before the IVF treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cycle cancellation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AMH Group</title>
          <description>Serum AMH measurement
Serum AMH measurement: Serum AMH is measured one month before the IVF treatment</description>
        </group>
        <group group_id="B2">
          <title>AFC Group</title>
          <description>AFC measurement
AFC measurement: Early follicular phase AFC is measured one month before the IVF treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="34" upper_limit="38"/>
                    <measurement group_id="B2" value="35" lower_limit="33" upper_limit="37"/>
                    <measurement group_id="B3" value="35" lower_limit="34" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Having Desired Ovarian Response</title>
        <description>Percentage of subjects with number of oocytes retrieved being between 6 and14</description>
        <time_frame>One single time point, i.e. at the time of oocyte retrieval</time_frame>
        <population>Intention-to-treat basis. Those not proceeding with ovarian stimulation or oocyte retrieval were regarded as not having desired ovarian response</population>
        <group_list>
          <group group_id="O1">
            <title>AMH Group</title>
            <description>Serum AMH measurement
Gonadotrophin dosing was based on serum AMH measured one month before the IVF treatment</description>
          </group>
          <group group_id="O2">
            <title>AFC Group</title>
            <description>AFC measurement
Gonadotrophin dosing was based on early follicular phase AFC measured one month before the IVF treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Having Desired Ovarian Response</title>
          <description>Percentage of subjects with number of oocytes retrieved being between 6 and14</description>
          <population>Intention-to-treat basis. Those not proceeding with ovarian stimulation or oocyte retrieval were regarded as not having desired ovarian response</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.479</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Requiring Step-up or Step-down of Gonadotrophin Dose Upon First Ultrasound Tracking</title>
        <description>The dose of gonadotrophin will be adjusted according to the ovarian response: if 5 or less follicles growing beyond 10 mm --&gt; step up if more than 15 follicles growing beyond 10 mm --&gt; step down</description>
        <time_frame>8th day of ovarian stimulation</time_frame>
        <population>Intention-to-treat analysis. Two subjects in the AFC group did not proceed with treatment and were regarded as not requiring dosage adjustment.</population>
        <group_list>
          <group group_id="O1">
            <title>AMH Group</title>
            <description>Serum AMH measurement
Gonadotrophin dosing was based on serum AMH measured one month before the IVF treatment</description>
          </group>
          <group group_id="O2">
            <title>AFC Group</title>
            <description>AFC measurement
Gonadotrophin dosing was based on early follicular phase AFC measured one month before the IVF treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Requiring Step-up or Step-down of Gonadotrophin Dose Upon First Ultrasound Tracking</title>
          <description>The dose of gonadotrophin will be adjusted according to the ovarian response: if 5 or less follicles growing beyond 10 mm --&gt; step up if more than 15 follicles growing beyond 10 mm --&gt; step down</description>
          <population>Intention-to-treat analysis. Two subjects in the AFC group did not proceed with treatment and were regarded as not requiring dosage adjustment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AMH Group</title>
          <description>Serum AMH measurement
Gonadotrophin dosing was based on serum AMH measured one month before the IVF treatment</description>
        </group>
        <group group_id="E2">
          <title>AFC Group</title>
          <description>AFC measurement
Gonadotrophin dosing was based on early follicular phase AFC measured one month before the IVF treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raymond Li</name_or_title>
      <organization>The University of Hong Kong</organization>
      <phone>+852 22554517</phone>
      <email>raymondli@hku.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

